Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 5 min ago
Peer-reviewedCC BY 4.0Frontiers in Immunology

Epigenetic and metabolic plasticity of tumor cells in immunotherapy resistance

  • Jee-Eun Choi1,2
  • Inwha Baek3,4,5
5 affiliations
  1. 1Department of Pathology, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital
  2. 2Centre for Oncology and Immunology, Hong Kong Science Park
  3. 3College of Pharmacy, Kyung Hee University
  4. 4Institute of Regulatory Innovation through Science (IRIS), Kyung Hee University
  5. 5Regulatory Science, Department of Pharmacy, Graduate School, Kyung Hee University
Read full textPDFDOICite

Abstract

Cancer immunotherapy has demonstrated remarkable efficacy across multiple tumor types. Despite their significant clinical benefits, most patients with solid tumors remain refractory to immunotherapy, and initial responders frequently develop acquired resistance. Tumor plasticity is a key driver of resistance to cancer immunotherapy. In this review, we discuss how epigenetic and metabolic plasticity of tumor contributes to immunotherapy resistance and highlight emerging strategies targeting these programs to overcome resistance and improve clinical outcomes.

Related

  1. Epigenetic and RNA control of cancer stem cell plasticity and therapy resistance
    Rong Gao, Chenqi Nie, Zekai Hu +1
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  2. EZH2 at the epigenetic–immune interface: a dual-axis framework for tumor immune evasion and precision combination immunotherapy
    Yang Bai, Huimin Chen, Ye Gu
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  3. Targeting the Tumor Microenvironment Network to Overcome Immunotherapy Resistance in Non‐Small Cell Lung Cancer: Mechanisms to Clinical Translation
    Zengrui Wang, Zhuang Luo, Le Wang +3
    Cancer medicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. Metabolic signature of phosphoethanolamine and arginine pathways predicts prognosis and immunotherapy resistance in lung adenocarcinoma
    Tao Wang, Hongwei Li, Fei Ding
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  5. Early dynamics of a neutrophil interferon program drive immunotherapy resistance and limit durable anti-tumor immunity
    Y. Gao, E. Anning, L. Wang +29
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv

Cite

BibTeXRIS
BibTeX
@article{choi2026epigenetic,
  title = {{Epigenetic and metabolic plasticity of tumor cells in immunotherapy resistance}},
  author = {Jee-Eun Choi and Inwha Baek},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = oct,
  doi = {10.3389/fimmu.2026.1968997},
  url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1968997/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Epigenetic and metabolic plasticity of tumor cells in immunotherapy resistance
AU  - Jee-Eun Choi
AU  - Inwha Baek
PY  - 2026
DA  - 2026/10/05
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1968997
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1968997/full
AB  - Cancer immunotherapy has demonstrated remarkable efficacy across multiple tumor types. Despite their significant clinical benefits, most patients with solid tumors remain refractory to immunotherapy, and initial responders frequently develop acquired resistance. Tumor plasticity is a key driver of resistance to cancer immunotherapy. In this review, we discuss how epigenetic and metabolic plasticity of tumor contributes to immunotherapy resistance and highlight emerging strategies targeting these programs to overcome resistance and improve clinical outcomes.
SN  - 1664-3224
ER  -